Filing Details

Accession Number:
0001181431-12-031971
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-05-23 13:00:00
Reporting Period:
2012-05-21
Filing Date:
2012-05-23
Accepted Time:
2012-05-23 15:20:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
820096 Perrigo Co PRGO Pharmaceutical Preparations (2834) 382799573
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1242215 C Joseph Papa C/O Perrigo Company
515 Eastern Avenue
Allegan MI 49010
President And Ceo Yes Yes No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2012-05-21 10,912 $99.22 100,000 No 4 S Direct
Common Stock Acquisiton 2012-05-21 5,000 $20.50 105,000 No 4 M Direct
Common Stock Disposition 2012-05-21 5,000 $99.23 100,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option Right to Buy Disposition 2012-05-21 2,631 $0.00 2,631 $20.50
Common Stock Employee Stock Option Right to Buy Disposition 2012-05-21 2,369 $0.00 20,806 $20.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2010-08-10 2017-08-30 No 4 M Direct
18,437 2011-08-30 2017-08-30 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1sales plan amendment adopted by the reporting person on March 8, 2012. This 10b5-1 sales plan will expire on the close of business November 20, 2012.
  2. The price in column 4 is a weighted average. The prices actually received ranged from $99.04 to $99.37. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
  3. This transaction was effected pursuant to a Rule 10b5-1sales plan adopted by the reporting person on November 29, 2011. This 10b5-1 sales plan will expire on the close of business November 20, 2012.
  4. The price in column 4 is a weighted average. The prices actually received ranged from $99.06 to $99.42. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.